COVID-19. Vaccine manufacturer BioNTech hopes to return to normal within a year



[ad_1]

The general manager of the German company BioNTech, which has developed a vaccine against the new coronavirus with Pfizer, spoke on Sunday of a possible return to normal by next winter.

On the BBC, Professor Ugur Sahin estimated “Absolutely essential” have a high rate of vaccinations before the fall of 2021.

“If all goes well, we will start administering the vaccine later this year.”, he has declared. “Our goal is to deliver over 300 million doses of the vaccine through April next year, which would allow us to start making an impact.” against the virus, which has killed more than 1.3 million people worldwide.

Several vaccines in stage 3

“The biggest impact will happen until the summer. The summer will help us anyway because the infection rate will drop “, He continued. “What is absolutely essential is that we have a high vaccination rate before the fall / winter of next year”.

“I’m confident it will happen” because many vaccine manufacturers have been asked to increase production, he said, adding: “We could have a normal winter next year”.

According to Pfizer and BioNTech, their vaccine is “90% effective” against Covid-19, according to the large-scale phase 3 trial still in progress, the last step before an application for approval. Several other vaccines are also in this phase of research, suggesting the horizon for a return to normal.

.

[ad_2]
Source link